Many characteristics of the putative protein encoded by varicella-zoster virus (VZV) open reading frame (ORF) 14 indicate that it is a glycoprotein, which has been designated gpV. To identify the protein products of the gene, the coding sequences were placed under the control of the vaccinia virus p7.5 promoter and recombinant vaccinia viruses were constructed. Heterogeneous polypeptides with molecular weights of 95,000 to 105,000 (95K to 105K polypeptides) were expressed in cells infected by a vaccinia virus recombinant (vKIP5) containing ORF 14 from VZV Scott but were not expressed by control vaccinia viruses. These polypeptides were recognized by antibodies present in human sera that contained high levels of anti-VZV antibodies. Conversely, antisera raised in rabbits inoculated with vKIP5 reacted specifically with heterogeneous 95K to 105K polypeptides present in VZV Scott-infected but not uninfected cells; these polypeptides show a patchy plasma membrane fluorescence pattern in VZV Scott-infected cells. These same antisera neutralized VZV strain Scott infectivity in the absence of complement. Endoglycosidase F treatment of isolated gpV polypeptides and tunicamycin treatment of cells infected with the vKIP5 recombinant indicated that the polypeptides were glycosylated. Three sets of data imply that the VZV strain Oka, which has been used to produce a live attenuated virus vaccine, accumulates low levels of gpV polypeptides relative to wild-type strains: (i) blocking of antibodies in human sera with excess VZV Oka-infected cell antigen yielded residual antibodies which were reactive with the 95K to 105K gpV polypeptides expressed in cells infected by VZV strain Scott and by the vKIP5 vaccinia virus recombinant, but not with Oka-infected cell polypeptides; (ii) antisera raised to vKIP5 detected very low levels of reactive polypeptides made in VZV Oka-infected cells and neutralized VZV Oka virus much less efficiently than VZV Scott; and (iii) comparisons of the reactivity of sera from live attenuated virus vaccine vaccinees with sera derived from patients recovering from wild-type infections indicated greatly reduced levels of gpV-specific antibodies in some vaccinees.
Varicella-zoster virus (VZV) is the causative agent of two clinical manifestations: varicella, or chickenpox, which is usually contracted in childhood, and zoster, or shingles, which is a painful disease caused by reactivation of the latent virus. Zoster is of growing significance, occurring more frequently as the elderly population increases. Immunocompromised individuals, particularly susceptible children, suffer higher morbidity and some mortality from both diseases. This spurred the development of a live attenuated virus vaccine (LAVV) aimed at prevention of varicella in leukemic and immunosuppressed children (34) . LAVV was derived by passage of a virus isolate (strain Oka) through semipermissive and permissive tissue cultures. It is currently undergoing extensive clinical trials throughout the world (15) and might be given to children as a routine vaccination in early childhood, possibly in conjunction with the measles, mumps, and rubella vaccines (1) . The molecular basis for its attenuation is not known.
The identification of VZV-specified glycoproteins is of primary importance in studies of the virus and of virus vaccines, since they are likely to be among the primary targets for both humoral and cellular immune responses in the infected individual. Analysis of the sequence of the VZV genome has revealed at least five whose products are designated gpl, gpII, gpIII, gpIV, and gpV (4, 5, 21) . These have been defined on the basis of typical glycoprotein structural characteristics predicted from ORFs within VZV DNA (10, 19, 21) . Initial characterization of polypeptides synthesized in cells infected with VZV revealed a large number of electrophoretically heterogeneous glycoprotein species. Monoclonal antibodies which react with subsets of these virus-specified glycoproteins have been isolated, and their use has shown that many of the species are related by being either alternately processed forms of the same polypeptide backbone (12, 13, 16, 20, (26) (27) (28) or are multiple forms of the same polypeptide linked by disulfide bonds (e.g., gpII; 16, 36) . Collectively, these experiments allowed the identification of glycoproteins expressed by genes encoding VZV gpl (ORF 68) , gpII (ORF 31), and gpIII (ORF 37) (10-13, 16, 20, 28, 37) . The products of VZV ORF 67 (gpIV) have also been identified recently by using antibodies raised to a synthetic peptide derived from part of the predicted amino acid sequence of the ORF (6) and by a cross-reactive site present on both gpI and gpIV (35) . GpI, gpII, and gpIII have all been shown to possess epitopes which are targets for neutralizing antibodies, and complement appears to be required for neutralization by anti-gpI antisera (11-13, 20, 37) . Antibodies to these three glycoproteins plus many other, as yet unidentified, polypeptides are found in sera derived from patients recovering from VZV infections (8) .
We and others have described the fifth ORF (no. 14) with the potential to express a glycoprotein (gpV), but a polypeptide(s) expressed from this gene has yet to be described (5, 21) . The predicted amino acid sequence bears a limited homology to that of herpes simplex virus (HSV) glycoprotein C (gC), primarily at the carboxy terminus. Unlike gC, the VZV gene possesses unusual in-frame intragenic 42-base-pair repeating sequences that show a strain-dependent copy number variation (21) . For example, the Oka strain has four fewer copies of the repeat element than do several wild-type strains (e.g., Scott), with a correspondingly smaller ORF for gpV.
Here we identify the protein products of VZV ORF 14, demonstrate their glycoprotein nature (gpV), and show that antibodies directed against gpV may play a role in virus neutralization. We also present evidence that the LAVV strain Oka is defective in the accumulation of gpV.
MATERIALS AND METHODS Cells and viruses. The origin and growth of VZV strains have previously been described (21, 30, 33 phosphate-precipitated DNA from gene 14-containing clones (23, 24) . TK-virus was selected by growth on TK-143 cells in the presence of 5-bromodeoxyuridine, and the resulting recombinants were assayed for blue plaque production in the presence of 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (3) . At least three rounds of plaque purification were used for each isolate. Verification that recombinant viruses contained the entire gene 14 insert was obtained by probing gelfractionated, BamHI-EcoRI-restricted whole infected cell DNA immobilized on nitrocellulose (32) with the insert fragment labeled by using nick repair with [32P]dCTP (3, 000 Ci/nmol).
Recombinant vaccinia virus expressing VZV gpl was prepared in a similar fashion, except that a BglI-SmaI fragment containing the entire gpl ORF was isolated, treated with T4 DNA polymerase and nucleotides, and inserted into the SmaI site of pSC11. A recombinant virus containing these sequences was isolated (vKIP9) and found to express several heterogeneous polypeptides that reacted with human antisera containing high levels of VZV antibodies. A similar vaccinia virus recombinant expressing products from the gpl gene has previously been described (2 (29) . The blots were then treated with 10% (wt/vol) Carnation instant nonfat dried milk in buffer containing 0.15 M NaCl, 50 mM Tris hydrochloride, pH 7.6, 0.05% (vol/vol) Tween 20, 10 mM EDTA and subsequently reacted with antisera diluted 1:100 in the same buffer containing 0.1% (wt/vol) bovine serum albumin and 1% (wt/vol) dried milk. Bound immunoglobulins were detected with 125I-labeled Staphylococcus protein A (105 dpm/ml). Absorbed sera were prepared by mixing infected cell sonic extracts and sera at the ratio of 108 cell equivalents per 0.1 ml of antiserum in a manner similar to that described previously (31) . Antigen-antibody complexes were removed by high-speed centrifugation prior to use.
Tunicamycin and endoglycosidase treatment. For tunicamycin treatment, vaccinia virus-infected cells were incubated from 4 h after infection until harvest (24 h) in medium containing 1.5 p.g of tunicamycin (Calbiochem-Behring, La Jolla, Calif.) per ml. For endoglycosidase F treatment, cells infected with a vaccinia virus recombinant were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and the region of the gel containing gpV was excised. Protein was eluted in 10 mM Tris hydrochloride, pH 7.5-1 mM EDTA and incubated with 0.5 U of endoglycosidase F (Boehringer Mannheim) in 0.5% (vol/vol) Triton X-100-0.5% (vol/vol) 3-mercaptoethanol-5 mM EDTA and either 100 mM sodium acetate, pH 4.8 (low-pH incubation), or 100 mM potassium phosphate, pH 8.0 (high-pH incubation). After incubation, protein was precipitated with 10% (wt/vol) trichloracetic acid and Western blotted as described above, following SDS-PAGE.
Production of antisera. Recombinant vaccinia virus was grown and purified as described previously (23, 24) . At several sites, 5 x 107 PFU was injected subcutaneously into rabbits, and injection was repeated after 4 weeks; serum was collected at 2-week intervals following the second inoculation and tested for reactivity by Western blot analysis against VZV-infected cells.
Virus neutralization. HFF cells were infected with VZVinfected cells at a 20:1 ratio. After approximately 10% cytopathic effect had developed, the cells were trypsinized and reseeded in the same flask. This step was repeated 24 h later, with the addition of an equal number of uninfected cells. Cells were harvested 24 to 48 h later and ultrasonically disrupted in minimal essential medium with 20% (vol/vol) fetal calf serum. A 0.4-ml portion of sonic extract containing 102 to 104 PFU was mixed with 0.1 ml of the appropriate antiserum diluted in phosphate-buffered saline. After incubation for 2 h, the mixture was applied to subconfluent HFF monolayers, and plaques were counted after 4 to 6 days.
Indirect immunofluorescence. Subconfluent monolayers of HFF cells were grown on glass cover slips and infected with VZV Scott as described above. Two to four days later, cells were washed three times in ice-cold phosphate-buffered saline and fixed in acetone at -20°C for 10 min. Cover slips were then rehydrated in phosphate-buffered saline containing 10% (vol/vol) fetal calf serum for 15 min at room temperature. Following this, they were incubated with an appropriate dilution of antibody for 1 h and then washed three times with phosphate-buffered saline. Cells were then exposed to goat anti-rabbit immunoglobulin G conjugated with rhodamine (Boehringer Mannheim) for 1 h and washed three times with phosphate-buffered saline. The cover slips were then mounted in 50% glycerol and viewed with a phase-fluorescence microscope (Carl Zeiss Inc., Thornwood, N.J.).
RESULTS
To identify the products of ORF 14, we have used anti-VZV antibodies present in human sera to detect products (gpV) from coding sequences expressed in vaccinia virus recombinants. We have also used antisera to this recombinant as a specific reagent to examine the properties of gpV in VZV-infected cells.
Construction of vaccinia virus recombinants expressing gpV. Figure 1 shows the construction of the plasmid containing the sequences used to create gpV-expressing vaccinia virus recombinants. A plasmid containing the BamHI F fragment from VZV strain Scott DNA was cleaved with BstNI (which cleaves 3 base pairs upstream of the second in-frame ATG of the ORF) and AluI (which cleaves 136 base pairs downstream from the end of the ORF and downstream from a possible polyadenylation signal; Fig. 1 ). The first ATG in the ORF lies 93 base pairs upstream from the second and has the context 5'TTCCCAATGTCGAAA 3' (5, 21). We considered it more likely that the second ATG, rather than the first, is used because it is immediately followed by a hydrophobic sequence which is the likely signal sequence for gpV; this ATG also has the better Kozak (22) context. This fragment was then inserted into the unique SmaI site of pSC11 (3), under the control of the vaccinia virus early-late promoter p7.5. The construction was verified by sequencing the promoter-gpV fusion point (data not shown). The resulting plasmid (pKIP5) also contains Escherichia coli P-galactosidase (LacZ) under the control of the vaccinia virus promoter pll. pKIP5 was then transfected into vaccinia virus-infected cells, and several TK-vaccinia recombinants expressing P-galactosidase were isolated. Two of these recombinants were plaque purified and then analyzed for expression from the gpV gene. Both recombinants yielded identical results in the assays to be described.
Expression from gpV-vaccinia virus recombinants. Western blots of infected cells were prepared and reacted with human antisera obtained from patients recovering from VZV infections. Figure 2 shows the reactivity of convalescent-phase antiserum from a zoster patient, with blots derived from equivalent quantities of HFF cells infected with VZV Scott (lane A), uninfected cells (lane B), the vKIP5 vaccinia virus recombinant (lane C), and vSC8, a vaccinia virus recombinant containing pSC8 sequences but no VZV DNA (lane D). The antiserum clearly reacts specifically with polypeptides present in the VZV-infected, but not uninfected, cell extracts. The vaccinia virus recombinant containing the gpV gene expressed polypeptides with molecular weights of 95,000 to 105,000 (95K to 105K polypeptides) which reacted specifically with this and several other convalescent-phase sera, indicating that the proteins expressed from VZV gene 14 are significant immunogens in natural VZV infection. These reactive polypeptides must be products of ORF 14, since the control virus, vSC8, expressed no polypeptides reactive with the VZV convalescent sera.
Rabbits were inoculated with vKIP5 to generate antiserum against gpV, and this serum was used to probe the cellular location of gpV by indirect immunofluorescence. The results are shown in Fig. 3 , and they show two samples of VZV Scott-infected cells probed with anti-vKIP5 antiserum (Fig.  3A and B) ; in both samples, the fluorescence appears to be associated with the plasma membrane and to be patchy in many cells. Both preimmune sera (Fig. 3C ) and uninfected cells (Fig. 3D) give faint overall background fluorescence.
The glycoprotein nature of gpV. 95K to 105K polypeptides. These are larger than would be predicted from the ORF (61K), but since there are five potential sites for N-linked glycosylation predicted from the sequence (21) , this discrepancy is likely to be due to addition of carbohydrate. Two approaches were used to investigate this: in vivo tunicamycin treatment and in vitro endoglycosidase degradation. These indirect methods had to be used because none of our anti-gpV antibodies works well in immunoprecipitation experiments. In the first approach, HFF cells infected with the vKIP5 were incubated with tunicamycin from 8 to 24 h postinfection and then harvested for Western blot analysis with convalescent-phase serum from a zoster patient. The results (Fig. 4) show that tunicamycin, which inhibits N-linked glycosylation, significantly reduces the formation of 95K to 105K polypeptides, revealing two novel major polypeptides of 64K and 58K and two minor polypeptides of 60K and 68K. We interpret this result to suggest that the 58K polypeptide represents unmodified gene 14 product, while the other species are partially modified; some limited proteolytic digestion may also have taken place. The small amount of mature gpV seen was probably synthesized prior to addition of tunicamycin, since VZV infections have to be carried out with whole cells. Similar blots probed with anti-p-galactosidase antiserum (vKIP5 has an active 3-galactosidase gene) showed no difference in either the amount or the size of 0-galactosidase as a result of tunicamycin treatment (data not shown).
In the second series of experiments, gpV was isolated from v.KIP5-infected cells by elution from polyacrylamide gels and incubated in vitro with endoglycosidase F, which trims both N-linked high-mannose simple and low-mannose complex oligosaccharides. Incubation products were concentrated by trichloroacetic acid precipitation, blotted to nitrocellulose after SDS-PAGE, and probed by using a convalescent-phase human serum. The results (Fig. 5) show (Fig. 6c, arrow) , which is the same size as gpV; other more minor species were inconsistently seen. To verify that this absorbed-out antibody is directed at gpV, it was used to probe Western blots of cells infected with the vaccinia virus ORF 14 recombinant, vKIP5. The results (Fig. 7) show that both the vKIP5 recombinant (lane b)-and Scott (lane d)-infected cells give analogous reactivity at 95K to 105K, strongly suggesting that Oka-infected cell extracts contain very little gpV. As further confirmation of this deficiency in Oka, antiserum was prepared from rabbits infected with the vKIP5 and used as a specific probe for gpV. Identical Western blots of Scott, Oka, and uninfected cell polypeptides were reacted with either a VZV convalescentphase human serum (Fig. 8a) or with the anti-vKIP5 serum (Fig. 8b) . As expected, anti-vKIP5 antibodies bound specifically to 95K to 105K polypeptides present in Scott-infected cells, but not in uninfected cells. In VZV Oka-infected cells, however, only trace amounts of gpV of the smaller size expected from the ORF are visible. These data, therefore, all point to defective accumulation of gpV in VZV Oka-infected cells.
VZV neutralizing activity in gpV-specific antisera. We have been able to demonstrate, by using purified virion preparations, that gpV is present in the VZV particle (J. Hougland and P. R. Kinchington, unpublished observations). This raises the possibility, which could be tested with the recombinant-derived rabbit antiserum, that gpV might serve as a VZV-neutralizing antigen. The antiserum was mixed with VZV preparations and plated on HFF cells for infectivity assays. After 4 days, cells were fixed and plaques were counted; for comparison, both rabbit preimmune sera and convalescent-phase serum from a zoster patient were included in the assay. As can be seen in Table 1 , preimmune serum had a slight effect on VZV infectivity, at the highest dilution. In contrast, both human serum and gpV-specific rabbit serum substantially affected the infectivity of VZV Scott, reducing the titers by greater than 90% at dilutions up to 1/25 and by more than 50% at a dilution of 1/125. Inclusion of guinea pig complement with anti-gpV antiserum in the assay had no effect on neutralization of VZV. As predicted, VZV Oka was neutralized substantially less well than Scott by the anti-gpV serum, whereas human serum neutralizes both viruses to similar extents. These results imply that gpV is a target for complement-independent virus-neutralizing antibodies and that the level of neutralization of VZV Oka reflects small amounts of gpV in VZV Oka virions.
Reactivity of sera from vaccinees to gpV. The above data show that VZV Oka accumulates only trace levels of gpV compared with a wild-type strain. Recently we have shown that wild-type VZV strains in general, including several Japanese isolates, accumulate levels of gpV similar to that of Scott (P. R. Kinchington As a control, a number of sera from LAVV vaccinees were tested for reactivity to whole VZV-infected cell polypeptides on Western blots; three examples are shown in Fig.  9 . Sera gave variable responses in this test, and the presence of antibodies to gpV (or to other specific proteins) could not be assessed with any confidence, although some antisera gave strong responses (see, for example, Fig. 9b, lanes 1 and  2) . We have consistently observed that sera from natural infections appears more reactive than that from vaccinees, particularly in the <45K polypeptide range (compare Fig.  9a , lanes 1 and 2, with 9b, lanes 1 and 2, for example). However, when the sera were tested against recombinant gpV proteins, the results were well defined and interesting. With the wild-type antiserum, there is a strong response against gpV (Fig. 9a) . Of the three vaccinees' sera shown, two antisera showed very low levels of antibodies to gpV ( Fig. 9c and d ) but a third appeared positive for gpV (Fig.  9b) . Examination of the clinical history of those patients with LAVV sera positive for gpV suggested a correlation with vaccine-related problems; specifically, the serum in Fig. 9b was derived from a patient who had shown vaccine-induced zoster (A. A. Gershon, personal communication). As an internal control in all of these assays, we constructed and used a VZV gpl-expressing vaccinia virus recombinant (Oka is not defective in gpl accumulation); all of the sera tested showed anti-gpl activity (Fig. 9, lanes 4 (14, 17) .
Many herpesvirus glycoproteins are targets for neutralization by circulating antibodies. We show here that anti-gpV antibodies are able to neutralize VZV in the absence of complement, suggesting that gpV is exposed on the virion envelope; in addition, we demonstrate that gpV is a natural immunogen, since antibodies to gpV are present in sera from VZV convalescent patients. In this sense, gpV is similar to its other herpesvirus homologs; e.g., the HSV gC and the pseudorabies virus gpIII are major neutralization targets. Another feature which gpV shares with HSV gC is its intracellular location. Indirect immunofluorescence with anti-vKIP5 antisera shows patchy plasma membrane fluorescence in VZV-infected cells reminiscent of that shown by anti-HSV gC sera in HSV-infected cells (9) .
A surprising finding in this report is the lack of gpV associated with the VZV vaccine strain, Oka. Several The most likely reason for the Oka defect is that it simply makes less (or keeps less) gpV than other strains, and it should be noted that HSV gC (the partial homolog of gpV) is nonessential for virus growth (7, 18) . Alternatively, however, the Scott-Oka gpV divergence could be the result of major antigenic differences between gpV in these two viruses, rather than a quantitative difference in accumulation, although we feel that this is unlikely to be the case. The molecular basis for the gpV deficit in Oka strains is currently being investigated. Our preliminary observations suggest that Oka has a specific defect in transcription from the gpV gene (P. Ling, P. R. Kinchington 
